View Future GrowthTELCON RF PHARMACEUTICAL 과거 순이익 실적과거 기준 점검 0/6TELCON RF PHARMACEUTICAL은 연평균 14.6%의 비율로 수입이 증가해 온 반면, Electronic 산업은 연평균 5.5%의 비율로 증가했습니다. 매출은 연평균 4%의 비율로 증가했습니다.핵심 정보14.55%순이익 성장률21.37%주당순이익(EPS) 성장률Electronic 산업 성장률21.63%매출 성장률4.01%자기자본이익률-10.51%순이익률-26.54%최근 순이익 업데이트31 Dec 2025최근 과거 실적 업데이트분석 기사 • Mar 26Investors Shouldn't Be Too Comfortable With TELCON RF PHARMACEUTICAL's (KOSDAQ:200230) EarningsTELCON RF PHARMACEUTICAL. Inc.'s ( KOSDAQ:200230 ) stock was strong after they recently reported robust earnings...Reported Earnings • Mar 23Full year 2023 earnings released: EPS: ₩124 (vs ₩397 loss in FY 2022)Full year 2023 results: EPS: ₩124 (up from ₩397 loss in FY 2022). Revenue: ₩36.3b (up 31% from FY 2022). Net income: ₩13.9b (up ₩56.0b from FY 2022). Profit margin: 38% (up from net loss in FY 2022). Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings.모든 업데이트 보기Recent updates공시 • Apr 18TELCON RF PHARMACEUTICAL. Inc. announced that it has received KRW 3 billion in funding from Nuon Co., Ltd.On April 17, 2026. TELCON RF PHARMACEUTICAL. Inc. announced that it has closed the transaction.New Risk • Apr 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (₩28.1b market cap, or US$19.1m).공시 • Apr 09TELCON RF PHARMACEUTICAL. Inc. announced that it expects to receive KRW 3 billion in funding from Nuon Co., Ltd.TELCON RF PHARMACEUTICAL. Inc. has announced to issue 3,000,000 common stock at a price of KRW 1000 per share for gross proceeds of KRW 3,000,000,000 on April 7, 2026. The transaction include investor participation from Nuon Co., Ltd. The transaction has been approved by board of directors. The transaction is expected to close on April 17, 2026. All the securities issued pursuant to the offering is subject to hold period of one year.공시 • Mar 06TELCON RF PHARMACEUTICAL. Inc., Annual General Meeting, Mar 27, 2026TELCON RF PHARMACEUTICAL. Inc., Annual General Meeting, Mar 27, 2026, at 09:00 Tokyo Standard Time. Location: conference room, 205, goan-ro 51beon-gil, baegam-myeon, cheoin-gu, gyeonggi-do, yongin South Korea분석 기사 • Feb 05Some Shareholders Feeling Restless Over TELCON RF PHARMACEUTICAL. Inc.'s (KOSDAQ:200230) P/S RatioWith a median price-to-sales (or "P/S") ratio of close to 0.9x in the Electronic industry in Korea, you could be...분석 기사 • Dec 02Is TELCON RF PHARMACEUTICAL (KOSDAQ:200230) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...분석 기사 • Sep 11More Unpleasant Surprises Could Be In Store For TELCON RF PHARMACEUTICAL. Inc.'s (KOSDAQ:200230) Shares After Tumbling 30%TELCON RF PHARMACEUTICAL. Inc. ( KOSDAQ:200230 ) shareholders won't be pleased to see that the share price has had a...공시 • Aug 13TELCON RF PHARMACEUTICAL. Inc. has completed a Follow-on Equity Offering in the amount of KRW 41.504364 billion.TELCON RF PHARMACEUTICAL. Inc. has completed a Follow-on Equity Offering in the amount of KRW 41.504364 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 10,822,520 Price\Range: KRW 3835 Discount Per Security: KRW 95.875 Transaction Features: Rights Offering분석 기사 • Jul 22TELCON RF PHARMACEUTICAL. Inc.'s (KOSDAQ:200230) 35% Price Boost Is Out Of Tune With RevenuesTELCON RF PHARMACEUTICAL. Inc. ( KOSDAQ:200230 ) shares have continued their recent momentum with a 35% gain in the...New Risk • May 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Market cap is less than US$100m (₩39.7b market cap, or US$28.9m).공시 • Apr 22+ 1 more updateTELCON RF PHARMACEUTICAL. Inc. announced that it has received KRW 12 billion in funding from Sangsangin Savings Bank, Sangsangin Plus Savings Bank Co.,Ltd.On April 22, 2025, TELCON RF PHARMACEUTICAL. Inc. closed the transaction,분석 기사 • Mar 24TELCON RF PHARMACEUTICAL. Inc.'s (KOSDAQ:200230) Shares May Have Run Too Fast Too SoonThere wouldn't be many who think TELCON RF PHARMACEUTICAL. Inc.'s ( KOSDAQ:200230 ) price-to-sales (or "P/S") ratio of...공시 • Mar 12TELCON RF PHARMACEUTICAL. Inc., Annual General Meeting, Mar 26, 2025TELCON RF PHARMACEUTICAL. Inc., Annual General Meeting, Mar 26, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 205, goan-ro 51beon-gil, cheoin-gu, gyeonggi-do, yongin South KoreaNew Risk • Dec 10New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₩7.19b (US$5.02m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₩7.19b market cap, or US$5.02m). Minor Risk Shareholders have been diluted in the past year (7.5% increase in shares outstanding).공시 • Nov 12ABION Inc. (KOSDAQ:A203400) agreed to acquire 7.56% stake in Vivozon, Inc. from TELCON RF PHARMACEUTICAL. Inc. (KOSDAQ:A200230) for KRW 20.1 billion.ABION Inc. (KOSDAQ:A203400) agreed to acquire 7.56% stake in Vivozon, Inc. from TELCON RF PHARMACEUTICAL. Inc. (KOSDAQ:A200230) for KRW 20.1 billion on November 11, 2024. The consideration consist of issue of 2.42 million common stock of ABION Inc. (KOSDAQ:A203400). The expected completion of the transaction is December 16, 2024.분석 기사 • Oct 23TELCON RF PHARMACEUTICAL. Inc.'s (KOSDAQ:200230) Popularity With Investors Is Under Threat From OverpricingWhen close to half the companies in the Electronic industry in Korea have price-to-sales ratios (or "P/S") below 0.7x...분석 기사 • Sep 06TELCON RF PHARMACEUTICAL (KOSDAQ:200230) Could Be At Risk Of Shrinking As A CompanyWhen it comes to investing, there are some useful financial metrics that can warn us when a business is potentially in...New Risk • May 28New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.7% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (3.7% increase in shares outstanding). Market cap is less than US$100m (₩84.7b market cap, or US$62.4m).Valuation Update With 7 Day Price Move • May 24Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩736, the stock trades at a trailing P/E ratio of 5.9x. Average trailing P/E is 15x in the Electronic industry in South Korea. Total loss to shareholders of 85% over the past three years.공시 • Apr 20+ 1 more updateTELCON RF PHARMACEUTICAL. Inc. announced that it expects to receive KRW 22 billion in funding from Sangsangin Savings Bank, Sangsangin Plus Savings Bank Co.,Ltd.TELCON RF PHARMACEUTICAL. Inc. announced a private placement to issue Series 20 Bearer Interest Unsecured Private Placement Convertible Bonds for the gross proceeds of KRW 22,000,000,000 on April 18, 2024. The transaction will include participation from new investors Sangsangin Savings Bank for KRW 12,000,000,000 and Sangsangin Plus Savings Bank Co.,Ltd. for KRW 10,000,000,000. The transaction has been approved by the shareholders of the company, restricted to a hold period and is expected to close on April 19, 2024. The bonds are 100% convertible into 29,891,304 shares at a fixed conversion price of KRW 736 from April 19, 2025 to March 19, 2027. The bonds bear 2% coupon rate, 5% maturity rate and matures on April 19, 2027.분석 기사 • Mar 26Investors Shouldn't Be Too Comfortable With TELCON RF PHARMACEUTICAL's (KOSDAQ:200230) EarningsTELCON RF PHARMACEUTICAL. Inc.'s ( KOSDAQ:200230 ) stock was strong after they recently reported robust earnings...Reported Earnings • Mar 23Full year 2023 earnings released: EPS: ₩124 (vs ₩397 loss in FY 2022)Full year 2023 results: EPS: ₩124 (up from ₩397 loss in FY 2022). Revenue: ₩36.3b (up 31% from FY 2022). Net income: ₩13.9b (up ₩56.0b from FY 2022). Profit margin: 38% (up from net loss in FY 2022). Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings.분석 기사 • Mar 13TELCON RF PHARMACEUTICAL. Inc. (KOSDAQ:200230) Investors Are Less Pessimistic Than ExpectedTELCON RF PHARMACEUTICAL. Inc.'s ( KOSDAQ:200230 ) price-to-sales (or "P/S") ratio of 2.4x may not look like an...Valuation Update With 7 Day Price Move • Dec 20Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₩818, the stock trades at a trailing P/E ratio of 9.1x. Average trailing P/E is 17x in the Electronic industry in South Korea. Total loss to shareholders of 86% over the past three years.Valuation Update With 7 Day Price Move • Nov 24Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩994, the stock trades at a trailing P/E ratio of 10.5x. Average trailing P/E is 17x in the Electronic industry in South Korea. Total loss to shareholders of 85% over the past three years.New Risk • Nov 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (10.0% average weekly change). Large one-off items impacting financial results. Shareholders have been diluted in the past year (3.0% increase in shares outstanding). Market cap is less than US$100m (₩109.3b market cap, or US$83.3m).Valuation Update With 7 Day Price Move • Nov 08Investor sentiment improves as stock rises 42%After last week's 42% share price gain to ₩977, the stock trades at a trailing P/E ratio of 10.4x. Average trailing P/E is 15x in the Electronic industry in South Korea. Total loss to shareholders of 84% over the past three years.분석 기사 • Apr 05Is TELCON RF PHARMACEUTICAL (KOSDAQ:200230) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Is New 90 Day High Low • Feb 24New 90-day low: ₩4,890The company is down 23% from its price of ₩6,360 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 29% over the same period.분석 기사 • Feb 03Did Business Growth Power TELCON RF PHARMACEUTICAL's (KOSDAQ:200230) Share Price Gain of 218%?TELCON RF PHARMACEUTICAL. Inc. ( KOSDAQ:200230 ) shareholders might be concerned after seeing the share price drop 20...Is New 90 Day High Low • Jan 28New 90-day low: ₩5,160The company is down 14% from its price of ₩6,010 on 30 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 56% over the same period.Is New 90 Day High Low • Jan 11New 90-day low: ₩5,490The company is down 31% from its price of ₩7,920 on 13 October 2020. The South Korean market is up 29% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 37% over the same period.Is New 90 Day High Low • Dec 23New 90-day low: ₩5,810The company is down 42% from its price of ₩9,990 on 24 September 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 15% over the same period.공시 • Nov 05Telcon RF Pharmaceutical Inc. announced that it has received KRW 40.65 billion in funding from Hanil Vacuum Co., Ltd.Telcon RF Pharmaceutical Inc. (KOSDAQ:A200230) announced a private placement of series 16 unregistered coupon non-guaranteed private convertible bonds for gross proceeds of KRW 4,290,000,000, series 17 unregistered coupon non-guaranteed private convertible bonds for gross proceeds of KRW 22,000,000,000, and series 18 unregistered coupon non-guaranteed private convertible bonds for gross proceeds of KRW 14,360,000,000, for aggregate gross proceeds of KRW 40,650,000,000 on November 3, 2020. The transaction will include participation from returning investor Hanil Vacuum Co., Ltd. (KOSDAQ:A123840) for the series 16 and 17 bonds and Evercore Investment Holdings for series 18 bonds. All the bonds carry a coupon rate of 3% and yield to maturity of 5%, and will mature on November 3, 2023. The series 16 bonds are fully convertible into 636,781 shares at a conversion price of KRW 6,737 per share which represents 0.74% stake in the company; the series 17 bonds are fully convertible into 3,265,548 shares at a conversion price of KRW 6,737 per share which represents 3.68% stake; and the series 18 bonds are fully convertible into 2,131,512 shares at a conversion price of KRW 6,737 per share which represents 2.43% stake. The conversion for all the bonds period starts from November 3, 2021 to October 3, 2023. The bonds have a hold period of one year. The transaction has been approved by the board of the directors of the company.공시 • Sep 29TELCON RF PHARMACEUTICAL. Inc. announced that it expects to receive KRW 30 billion in funding from Emmaus Life Sciences, Inc.TELCON RF PHARMACEUTICAL. Inc. (KOSDAQ:A200230) announced a private placement to issue series 15 non-guaranteed private convertible bonds with bearer interest for gross proceeds of KRW 30,000,000,000 on September 28, 2020. The transaction will include participation from returning investor Emmaus Life Sciences, Inc. (OTCPK:EMMA). The bonds carry a coupon rate and interest rate to maturity of 2.1%, and will mature on October 16, 2030. Interest to be paid every three months deferred to the interest payment date every three months from the day after the issue of the bond to the due date of repayment of the principal. The bonds are 100% convertible into 3,249,566 shares at a conversion price of KRW 9,232 per share which represents 3.80% stake in the company. The conversion period starts from October 16, 2021 and end on September 16, 2030. The bonds have a hold period of one year. The transaction is expected to close on October 16, 2020. The transaction has been approved by the board of the directors.매출 및 비용 세부 내역TELCON RF PHARMACEUTICAL가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이KOSDAQ:A200230 매출, 비용 및 순이익 (KRW Millions)날짜매출순이익일반관리비연구개발비31 Dec 2543,162-11,4565,56069930 Sep 2543,678-33,5056,28777330 Jun 2541,016-25,6026,21273231 Mar 2539,813-33,6706,97668431 Dec 2437,865-26,3206,45872330 Sep 2436,951-10,0485,4371,26130 Jun 2438,635-23,1865,7781,10131 Mar 2437,185-40,7384,96673631 Dec 2336,30713,9064,73673330 Sep 2332,84510,0915,63730630 Jun 2329,71310,5585,62060431 Mar 2328,46714,8245,4041,11331 Dec 2227,830-42,0845,3001,20830 Sep 2228,975-59,6907,6991,43230 Jun 2231,740-63,6267,4271,48031 Mar 2234,470-35,0667,5491,49831 Dec 2137,841-22,7678,7511,63530 Sep 2138,111-50,3866,8251,47230 Jun 2137,492-22,0445,2001,74931 Mar 2138,087-36,5534,5041,86531 Dec 2033,141-40,5374,4761,81730 Sep 2033,406-48,0865,7611,84830 Jun 2039,517-66,2618,4771,66531 Mar 2045,904-56,1878,0941,69131 Dec 1956,591-54,8107,4511,71030 Sep 1956,511-1,1376,5361,78930 Jun 1955,515615,9752,06231 Mar 1956,462-12,41010,0352,77331 Dec 1857,708-13,75511,3943,80030 Sep 1854,944-14,33811,8984,71530 Jun 1850,213-17,50112,5575,34031 Mar 1844,714-15,16711,1406,07731 Dec 1741,149-16,44010,4485,32830 Sep 1744,134-22,56111,1855,23330 Jun 1742,985-14,97511,3794,43231 Mar 1736,884-6,23810,0423,02931 Dec 1629,840-4,2398,6202,77230 Sep 1625,6401,1085,2871,94730 Jun 1624,909-9973,0661,84931 Mar 1625,465-4452,9861,78831 Dec 1528,5433482,9361,74730 Sep 1534,1132,1012,2952,83030 Jun 1547,2324,4472,9992,389양질의 수익: A200230 은(는) 현재 수익성이 없습니다.이익 마진 증가: A200230는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: A200230는 수익성이 없지만 지난 5년 동안 연평균 14.6%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 A200230의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: A200230은 수익성이 없어 지난 해 수익 성장률을 Electronic 업계(-11.9%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: A200230는 현재 수익성이 없으므로 자본 수익률이 음수(-10.51%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YTech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/15 11:36종가2026/05/15 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스TELCON RF PHARMACEUTICAL. Inc.는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Yang Ju ParkDaishin Securities Co. Ltd.
분석 기사 • Mar 26Investors Shouldn't Be Too Comfortable With TELCON RF PHARMACEUTICAL's (KOSDAQ:200230) EarningsTELCON RF PHARMACEUTICAL. Inc.'s ( KOSDAQ:200230 ) stock was strong after they recently reported robust earnings...
Reported Earnings • Mar 23Full year 2023 earnings released: EPS: ₩124 (vs ₩397 loss in FY 2022)Full year 2023 results: EPS: ₩124 (up from ₩397 loss in FY 2022). Revenue: ₩36.3b (up 31% from FY 2022). Net income: ₩13.9b (up ₩56.0b from FY 2022). Profit margin: 38% (up from net loss in FY 2022). Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings.
공시 • Apr 18TELCON RF PHARMACEUTICAL. Inc. announced that it has received KRW 3 billion in funding from Nuon Co., Ltd.On April 17, 2026. TELCON RF PHARMACEUTICAL. Inc. announced that it has closed the transaction.
New Risk • Apr 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (₩28.1b market cap, or US$19.1m).
공시 • Apr 09TELCON RF PHARMACEUTICAL. Inc. announced that it expects to receive KRW 3 billion in funding from Nuon Co., Ltd.TELCON RF PHARMACEUTICAL. Inc. has announced to issue 3,000,000 common stock at a price of KRW 1000 per share for gross proceeds of KRW 3,000,000,000 on April 7, 2026. The transaction include investor participation from Nuon Co., Ltd. The transaction has been approved by board of directors. The transaction is expected to close on April 17, 2026. All the securities issued pursuant to the offering is subject to hold period of one year.
공시 • Mar 06TELCON RF PHARMACEUTICAL. Inc., Annual General Meeting, Mar 27, 2026TELCON RF PHARMACEUTICAL. Inc., Annual General Meeting, Mar 27, 2026, at 09:00 Tokyo Standard Time. Location: conference room, 205, goan-ro 51beon-gil, baegam-myeon, cheoin-gu, gyeonggi-do, yongin South Korea
분석 기사 • Feb 05Some Shareholders Feeling Restless Over TELCON RF PHARMACEUTICAL. Inc.'s (KOSDAQ:200230) P/S RatioWith a median price-to-sales (or "P/S") ratio of close to 0.9x in the Electronic industry in Korea, you could be...
분석 기사 • Dec 02Is TELCON RF PHARMACEUTICAL (KOSDAQ:200230) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
분석 기사 • Sep 11More Unpleasant Surprises Could Be In Store For TELCON RF PHARMACEUTICAL. Inc.'s (KOSDAQ:200230) Shares After Tumbling 30%TELCON RF PHARMACEUTICAL. Inc. ( KOSDAQ:200230 ) shareholders won't be pleased to see that the share price has had a...
공시 • Aug 13TELCON RF PHARMACEUTICAL. Inc. has completed a Follow-on Equity Offering in the amount of KRW 41.504364 billion.TELCON RF PHARMACEUTICAL. Inc. has completed a Follow-on Equity Offering in the amount of KRW 41.504364 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 10,822,520 Price\Range: KRW 3835 Discount Per Security: KRW 95.875 Transaction Features: Rights Offering
분석 기사 • Jul 22TELCON RF PHARMACEUTICAL. Inc.'s (KOSDAQ:200230) 35% Price Boost Is Out Of Tune With RevenuesTELCON RF PHARMACEUTICAL. Inc. ( KOSDAQ:200230 ) shares have continued their recent momentum with a 35% gain in the...
New Risk • May 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Market cap is less than US$100m (₩39.7b market cap, or US$28.9m).
공시 • Apr 22+ 1 more updateTELCON RF PHARMACEUTICAL. Inc. announced that it has received KRW 12 billion in funding from Sangsangin Savings Bank, Sangsangin Plus Savings Bank Co.,Ltd.On April 22, 2025, TELCON RF PHARMACEUTICAL. Inc. closed the transaction,
분석 기사 • Mar 24TELCON RF PHARMACEUTICAL. Inc.'s (KOSDAQ:200230) Shares May Have Run Too Fast Too SoonThere wouldn't be many who think TELCON RF PHARMACEUTICAL. Inc.'s ( KOSDAQ:200230 ) price-to-sales (or "P/S") ratio of...
공시 • Mar 12TELCON RF PHARMACEUTICAL. Inc., Annual General Meeting, Mar 26, 2025TELCON RF PHARMACEUTICAL. Inc., Annual General Meeting, Mar 26, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 205, goan-ro 51beon-gil, cheoin-gu, gyeonggi-do, yongin South Korea
New Risk • Dec 10New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₩7.19b (US$5.02m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₩7.19b market cap, or US$5.02m). Minor Risk Shareholders have been diluted in the past year (7.5% increase in shares outstanding).
공시 • Nov 12ABION Inc. (KOSDAQ:A203400) agreed to acquire 7.56% stake in Vivozon, Inc. from TELCON RF PHARMACEUTICAL. Inc. (KOSDAQ:A200230) for KRW 20.1 billion.ABION Inc. (KOSDAQ:A203400) agreed to acquire 7.56% stake in Vivozon, Inc. from TELCON RF PHARMACEUTICAL. Inc. (KOSDAQ:A200230) for KRW 20.1 billion on November 11, 2024. The consideration consist of issue of 2.42 million common stock of ABION Inc. (KOSDAQ:A203400). The expected completion of the transaction is December 16, 2024.
분석 기사 • Oct 23TELCON RF PHARMACEUTICAL. Inc.'s (KOSDAQ:200230) Popularity With Investors Is Under Threat From OverpricingWhen close to half the companies in the Electronic industry in Korea have price-to-sales ratios (or "P/S") below 0.7x...
분석 기사 • Sep 06TELCON RF PHARMACEUTICAL (KOSDAQ:200230) Could Be At Risk Of Shrinking As A CompanyWhen it comes to investing, there are some useful financial metrics that can warn us when a business is potentially in...
New Risk • May 28New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.7% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (3.7% increase in shares outstanding). Market cap is less than US$100m (₩84.7b market cap, or US$62.4m).
Valuation Update With 7 Day Price Move • May 24Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩736, the stock trades at a trailing P/E ratio of 5.9x. Average trailing P/E is 15x in the Electronic industry in South Korea. Total loss to shareholders of 85% over the past three years.
공시 • Apr 20+ 1 more updateTELCON RF PHARMACEUTICAL. Inc. announced that it expects to receive KRW 22 billion in funding from Sangsangin Savings Bank, Sangsangin Plus Savings Bank Co.,Ltd.TELCON RF PHARMACEUTICAL. Inc. announced a private placement to issue Series 20 Bearer Interest Unsecured Private Placement Convertible Bonds for the gross proceeds of KRW 22,000,000,000 on April 18, 2024. The transaction will include participation from new investors Sangsangin Savings Bank for KRW 12,000,000,000 and Sangsangin Plus Savings Bank Co.,Ltd. for KRW 10,000,000,000. The transaction has been approved by the shareholders of the company, restricted to a hold period and is expected to close on April 19, 2024. The bonds are 100% convertible into 29,891,304 shares at a fixed conversion price of KRW 736 from April 19, 2025 to March 19, 2027. The bonds bear 2% coupon rate, 5% maturity rate and matures on April 19, 2027.
분석 기사 • Mar 26Investors Shouldn't Be Too Comfortable With TELCON RF PHARMACEUTICAL's (KOSDAQ:200230) EarningsTELCON RF PHARMACEUTICAL. Inc.'s ( KOSDAQ:200230 ) stock was strong after they recently reported robust earnings...
Reported Earnings • Mar 23Full year 2023 earnings released: EPS: ₩124 (vs ₩397 loss in FY 2022)Full year 2023 results: EPS: ₩124 (up from ₩397 loss in FY 2022). Revenue: ₩36.3b (up 31% from FY 2022). Net income: ₩13.9b (up ₩56.0b from FY 2022). Profit margin: 38% (up from net loss in FY 2022). Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings.
분석 기사 • Mar 13TELCON RF PHARMACEUTICAL. Inc. (KOSDAQ:200230) Investors Are Less Pessimistic Than ExpectedTELCON RF PHARMACEUTICAL. Inc.'s ( KOSDAQ:200230 ) price-to-sales (or "P/S") ratio of 2.4x may not look like an...
Valuation Update With 7 Day Price Move • Dec 20Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₩818, the stock trades at a trailing P/E ratio of 9.1x. Average trailing P/E is 17x in the Electronic industry in South Korea. Total loss to shareholders of 86% over the past three years.
Valuation Update With 7 Day Price Move • Nov 24Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩994, the stock trades at a trailing P/E ratio of 10.5x. Average trailing P/E is 17x in the Electronic industry in South Korea. Total loss to shareholders of 85% over the past three years.
New Risk • Nov 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (10.0% average weekly change). Large one-off items impacting financial results. Shareholders have been diluted in the past year (3.0% increase in shares outstanding). Market cap is less than US$100m (₩109.3b market cap, or US$83.3m).
Valuation Update With 7 Day Price Move • Nov 08Investor sentiment improves as stock rises 42%After last week's 42% share price gain to ₩977, the stock trades at a trailing P/E ratio of 10.4x. Average trailing P/E is 15x in the Electronic industry in South Korea. Total loss to shareholders of 84% over the past three years.
분석 기사 • Apr 05Is TELCON RF PHARMACEUTICAL (KOSDAQ:200230) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Is New 90 Day High Low • Feb 24New 90-day low: ₩4,890The company is down 23% from its price of ₩6,360 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 29% over the same period.
분석 기사 • Feb 03Did Business Growth Power TELCON RF PHARMACEUTICAL's (KOSDAQ:200230) Share Price Gain of 218%?TELCON RF PHARMACEUTICAL. Inc. ( KOSDAQ:200230 ) shareholders might be concerned after seeing the share price drop 20...
Is New 90 Day High Low • Jan 28New 90-day low: ₩5,160The company is down 14% from its price of ₩6,010 on 30 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 56% over the same period.
Is New 90 Day High Low • Jan 11New 90-day low: ₩5,490The company is down 31% from its price of ₩7,920 on 13 October 2020. The South Korean market is up 29% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 37% over the same period.
Is New 90 Day High Low • Dec 23New 90-day low: ₩5,810The company is down 42% from its price of ₩9,990 on 24 September 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 15% over the same period.
공시 • Nov 05Telcon RF Pharmaceutical Inc. announced that it has received KRW 40.65 billion in funding from Hanil Vacuum Co., Ltd.Telcon RF Pharmaceutical Inc. (KOSDAQ:A200230) announced a private placement of series 16 unregistered coupon non-guaranteed private convertible bonds for gross proceeds of KRW 4,290,000,000, series 17 unregistered coupon non-guaranteed private convertible bonds for gross proceeds of KRW 22,000,000,000, and series 18 unregistered coupon non-guaranteed private convertible bonds for gross proceeds of KRW 14,360,000,000, for aggregate gross proceeds of KRW 40,650,000,000 on November 3, 2020. The transaction will include participation from returning investor Hanil Vacuum Co., Ltd. (KOSDAQ:A123840) for the series 16 and 17 bonds and Evercore Investment Holdings for series 18 bonds. All the bonds carry a coupon rate of 3% and yield to maturity of 5%, and will mature on November 3, 2023. The series 16 bonds are fully convertible into 636,781 shares at a conversion price of KRW 6,737 per share which represents 0.74% stake in the company; the series 17 bonds are fully convertible into 3,265,548 shares at a conversion price of KRW 6,737 per share which represents 3.68% stake; and the series 18 bonds are fully convertible into 2,131,512 shares at a conversion price of KRW 6,737 per share which represents 2.43% stake. The conversion for all the bonds period starts from November 3, 2021 to October 3, 2023. The bonds have a hold period of one year. The transaction has been approved by the board of the directors of the company.
공시 • Sep 29TELCON RF PHARMACEUTICAL. Inc. announced that it expects to receive KRW 30 billion in funding from Emmaus Life Sciences, Inc.TELCON RF PHARMACEUTICAL. Inc. (KOSDAQ:A200230) announced a private placement to issue series 15 non-guaranteed private convertible bonds with bearer interest for gross proceeds of KRW 30,000,000,000 on September 28, 2020. The transaction will include participation from returning investor Emmaus Life Sciences, Inc. (OTCPK:EMMA). The bonds carry a coupon rate and interest rate to maturity of 2.1%, and will mature on October 16, 2030. Interest to be paid every three months deferred to the interest payment date every three months from the day after the issue of the bond to the due date of repayment of the principal. The bonds are 100% convertible into 3,249,566 shares at a conversion price of KRW 9,232 per share which represents 3.80% stake in the company. The conversion period starts from October 16, 2021 and end on September 16, 2030. The bonds have a hold period of one year. The transaction is expected to close on October 16, 2020. The transaction has been approved by the board of the directors.